MS Therapies: Clinical Results Offer Hope
“`html
Diabetes Drug Offers hope for multiple Sclerosis nerve Repair
Table of Contents
What is Multiple Sclerosis?
Multiple Sclerosis (MS) is the most common neurological condition in young adults, affecting nearly 3 million people worldwide, with over 150,000 patients in the UK alone. Most individuals are diagnosed in their 30s and 40s.
The disease occurs when the immune system mistakenly attacks the myelin sheaths – the protective fatty coatings around nerve fibers in the brain and spinal cord. This damage disrupts the transmission of electrical signals, leading to a range of neurological symptoms.
Symptoms of Multiple Sclerosis
Initial symptoms can vary widely but often include:
- Tingling and numbness
- Loss of balance
- Vision problems
Because these symptoms can be indicative of other illnesses, obtaining a definitive diagnosis can take time.
types of Multiple Sclerosis
MS presents in different forms:
- Relapsing MS: Characterized by periods of symptom flare-ups (relapses) followed by periods of remission, where myelin sheaths are damaged and then partially repaired.
- Progressive MS: A more debilitating form where the body loses its ability to repair damaged myelin, leading to a steady decline in nerve function and progressive disability. Symptoms can include tremors, speech problems, muscle stiffness, and spasms, perhaps requiring the use of walking aids or wheelchairs.
The Potential of Clemastine and Metformin
For over a decade, researchers have investigated the potential of clemastine, an antihistamine, to stimulate the body’s natural myelin repair mechanisms. Initial studies, such as the research published in PubMed, showed promise, but the effect size was small. The ReBuild trial at the University of California,San Francisco confirmed some improvement in nerve function,but again,the effect was limited.